ArticleFrontiers in pharmacology2022

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.

Yen-Chieh Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.